Search Results
Your search for ,USE matches 11256 pages
Showing 7851 - 7900Selected Abstracts From 2015 ASH Annual Meeting: Part 2
Here are several more abstracts selected from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting therapeutics in acute leukemias and myelodysplastic syndromes. For five other top abstracts on therapies for acute leukemias and myelodysplastic ...
Expanded Approval of Pembrolizumab in Unresectable or Metastatic Melanoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 18, 2015, approval of the programmed cell death...
A Famous French Oncologist’s Gastronomic Advice for Reducing Cancer Risk
BookmarkTitle: The Anti-cancer Diet: Reduce Cancer Risk Through the Foods You EatAuthors: David Khayat, MDPublisher: W.W. Norton & CompanyPublication date: April 2015Price: $26.95; hardcover, 288 pages In 2002, David Khayat, MD, was in Turkey on holiday with friends when he received a call...
Fear’s Many Deleterious Consequences
Bookmark Title: The Fear Cure: Cultivating Courage as Medicine for the Body, Mind, and Soul Author: Lissa Rankin, MD Publisher: Hay House, Inc Publication date: February 23, 2015 Price: $25.99; hardcover, 336 pages Fear is a healthy survival mechanism, a fight-or-flight response designed to put...
A Pioneering Oncologist’s Roadmap Forward
Bookmark Title: The Death of Cancer: After Fifty Years on the Front Lines of Medicine, a Pioneering Oncologist Reveals Why the War on Cancer Is Winnable—and How We Can Get There Authors: Vincent T. DeVita, Jr, MD, and Elizabeth DeVita-Raeburn Publisher: Farrar, Straus and Giroux Publication date:...
Looking at the Real-World Effects of Genetic Testing
According to the most recent estimates, 55% to 65% of women who inherit the BRCA1 mutation and about 45% of women who inherit the BRCA2 mutation will develop breast cancer by the time they are 70 years old. There is also a substantial increase in the probability of developing ovarian cancers in...
Defibrotide Under Review for Transplant-Related Complication
A potentially fatal complication of hematopoietic stem cell transplantation may be reversed with the use of a novel drug currently under priority review at the U.S. Food and Drug Administration (FDA). Hepatic veno-occlusive disease/sinusoidal obstruction syndrome is usually a serious complication...
How Cancer and Its Treatments Affect Cognitive Function
Although chemotherapy is often cited as the main culprit for diminishing cognitive function in patients with cancer, ushering the term “chemobrain” into the vernacular, research by Tim A. Ahles, PhD, and his colleagues is showing that multiple factors may contribute to the condition.1 Using breast...
Transcription Factor CDX2 May Be Prognostic Biomarker in Stage II and III Colon Cancer
In a study reported in The New England Journal of Medicine, Dalerba et al found that absence of the transcription factor CDX2, although prognostic for poor outcome in stage II and III colon cancer vs cancers with CDX2 expression, identified a subgroup of high-risk patients who appeared to benefit...
New Assay Detects Persistent Disease in Leukemia Patients Thought to Be in Remission
The outcomes of chronic myeloid leukemia (CML) have dramatically improved as the result of tyrosine kinase inhibitor treatment. Use of a tyrosine kinase inhibitor regimen can lower the blood CML biomarker to levels imperceptible by current detection methods. For patients in “molecular...
Bone Loss Associated With Leukemia Therapy Occurs Sooner Than Previously Thought
Investigators at Children’s Hospital Los Angeles (CHLA) have found that significant bone loss occurs during the first month of chemotherapy for acute lymphoblastic leukemia (ALL), which is far earlier than previously assumed. Results of the study were published by Orgel et al in the...
World Cancer Day 2016: We Can. I Can.
Cancer will kill more than 8 million people worldwide this year, which is equivalent to the entire population of New York. Half of these will be people of working age (30–69 years old). It has been estimated that the cost implications on world economies caused by cancer and the other...
For Postmenopausal Women With Ductal Carcinoma in Situ: NSABP B-35 and IBIS-II DCIS Trials Offer a Choice of Endocrine Therapy
The past year has produced an embarrassment of riches regarding the value of aromatase inhibitors for women with ductal carcinoma in situ of the breast. The long-awaited NSABP B-35 study matured and was reported by Margolese and colleagues at the 2015 ASCO Annual Meeting this past summer, followed...
ASCO Names Advance of the Year, Highlights Major Top Research Trends
Research is the bedrock of progress against cancer, and discoveries in cancer biology are moving from bench to bedside faster than ever. No recent advance has been more transformative than the rise of immunotherapy, particularly over the past year, making this treatment strategy ASCO’s Advance of...
Tamoxifen or Anastrozole for Ductal Carcinoma in Situ?
Ductal carcinoma in situ is a relatively benign form of breast cancer (stage 0), yet up to 10% of women with ductal carcinoma in situ will have a recurrence within 10 years. At present, there is no way to identify which women will recur, so standard treatment is lumpectomy plus radiation therapy....
Synthetic 2D Mammography May Hold Advantages Over 2D/3D Mammography
In screening for breast cancer, results from a study in the United Kingdom suggest that the use of “synthetic” two-dimensional (2D) mammography, rather than 2D/three-dimensional (3D) combinations, could save radiologists’ time and patients’ exposure to radiation as well as result in many fewer...
Selected Abstracts From 2015 San Antonio Breast Cancer Symposium
The 2015 San Antonio Breast Cancer Symposium (SABCS), hosted by the American Association for Cancer Research, the Cancer Therapy & Research Center at The University of Texas Health Sciences Center at San Antonio, and Baylor College of Medicine, was held in December 2015. As has been true for...
Expert Point of View: Thierry Facon, MD
Several experts commented that an all-oral regimen would bring convenience to the treatment of myeloma. Thierry Facon, MD, of Lille University Hospital in France, told The ASCO Post that although ixazomib (Ninlaro) may not be more active than other proteasome inhibitors, “It definitely has...
Studies Confirm and Extend the Benefits of Ixazomib in Multiple Myeloma
Patients with multiple myeloma now have access to an all-oral regimen, with the recent approval of the oral proteasome inhibitor ixazomib (Ninlaro) in previously treated patients. New pairings for the drug in relapsed/refractory and newly diagnosed patients are being studied, with investigators...
Expert Point of View: Sumanta K. Pal, MD
Commenting on both the CheckMate 025 and METEOR studies, Sumanta K. Pal, MD, Co-Director of the Kidney Cancer Program at City of Hope Comprehensive Cancer Center, Duarte, California, said, “Cabozantinib (Cometriq) will probably be approved for advanced renal cell carcinoma. There is debate about...
Expert Point of View: Christian K. Kollmannsberger, MD
Commenting on both of these studies, Christian K. Kollmannsberger, MD, of the British Columbia Cancer Center, Vancouver, Canada, said: “These studies suggest a more personalized approach to testicular cancer. Clearly, we need to do better than traditional risk factors used to guide therapy for...
Cancer Registries and the Evolving Role of Big Data in Cancer Care
In 1956, the American College of Surgeons encouraged the development of hospital-based registries, but for the most part, these efforts were clumsy, inaccessible card files of data. Today, advanced microcomputer technology has increased the ability to not only collect and cull cancer data but also...
Study Finds Association Between Androgen-Deprivation Therapy in Prostate Cancer and Risk of Alzheimer’s Disease
In a retrospective analysis reported in the Journal of Clinical Oncology, Nead et al found that use of androgen-deprivation therapy in the treatment of prostate cancer was associated with an increased risk of subsequent Alzheimer’s disease. Study Details In the study, a text-processing...
Higher Mortality Risk in Poor or Minority Adolescents and Young Adults vs White Patients With Hodgkin Lymphoma
Despite improvements in survival for adolescents and young adults diagnosed with Hodgkin lymphoma, the gains have not been shared uniformly across this patient population. A large population-based study by Keegan et al investigating the impact of race/ethnicity, socioeconomic status, influence of...
Higher Dietary Fiber Intake in Adolescence and Young Adulthood May Reduce Breast Cancer Risk
Women who eat more high-fiber foods during adolescence and young adulthood—especially fruits and vegetables—may have significantly lower breast cancer risk than those who eat less dietary fiber when young, according to a new large-scale study led by researchers at Harvard T.H. Chan...
UK Study Finds No Association Between Self-Reported Unhappiness and Mortality Risk
As reported in The Lancet by Liu et al, a study in UK women that attempted to adjust for the effect of health and lifestyle factors found that self-reported unhappiness was not associated with an increased risk of mortality from cancer or other conditions. Study Details The study involved data...
James O. Armitage, MD, FACP, FRCP, and Hagop M. Kantarjian, MD, on Advances in the Treatment of ALL
James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Hagop M. Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, discuss the diagnosis and genetics of ALL, differences in treating younger and older patients, and the latest data on the use of...
Samuel M. Silver, MD, PhD, and David S. Ettinger, MD, on the Characteristics of an Optimal Clinical Practice Guideline
Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and David S. Ettinger, MD, of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discuss the evolution of the NCCN Guidelines, the importance of including palliative care and survivorship...
John C. Grecula, MD, on the Role of Radiation Therapy in Management of SCLC
John C. Grecula, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of precision delivery of radiation for patients with small cell lung cancer and advances that include prophylactic cranial radiotherapy, ...
Amy Cyr, MD on Advances in Management of Early-Stage Breast Cancer
Amy Cyr, MD, of the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, discusses advances made in the treatment of early-stage breast cancer: less radiation and a shorter course, the rising use of molecular profiling, and less invasive surgery and reduced...
Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data
Daniel A. Vorobiof, MD, of the Sandton Oncology Centre, and Bernardo Leon Rapoport, MD, of The Medical Oncology Centre of Rosebank, discuss the first study to evaluate the efficacy and safety of a single dose of intravenous fosaprepitant. The use of this NK1 inhibitor and another (rolapitant) in a...
Thomas W. LeBlanc, MD, and Eric Roeland, MD, FAAHPM, on Palliative Care for Patients With Hematologic Malignancies
Thomas W. LeBlanc, MD, of Duke University Medical Center, and Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, discuss the use of palliative and hospice care for patients with solid tumors vs hematologic cancers and clinicians’ attitudes (Abstracts e20554...
Howard M. Sandler, MD, and Christopher Sweeney, MBBS, on Results of the RTOG 0521 Trial on Localized, High-Risk Prostate Cancer
Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discuss the improvement of overall survival with the use of adjuvant chemotherapy following androgen suppression and radiotherapy (Abstract LBA5002).
Areej El-Jawahri, MD, and Eric Roeland, MD, FAAHPM, on Quality of Life and Satisfaction With Care
Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, and Areej El-Jawahri, MD, of Massachusetts General Hospital, discuss two important studies on early palliative care and the use of anamorelin in advanced NSCLC with cachexia.
Andrew D. Seidman, MD, and Clifford A. Hudis, MD, on Breast Cancer Decision Analysis
Clifford A. Hudis, MD, and Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, discuss the use of the decision support system Watson for Oncology and results of the iCanCare study on second opinions (Abstracts 566 and 6508).
Howard M. Sandler, MD, Summarizes Results of the RTOG 0521 Trial on Localized, High-Risk Prostate Cancer
Howard M. Sandler, MD, of Cedars-Sinai Medical Center discusses the improvement of overall survival with the use of adjuvant chemotherapy following androgen suppression and radiotherapy (Abstract LBA5002).
Jimmie C. Holland, MD, and Tammy A. Schuler, PhD, on Talking With Patients About Their Distress: A Demonstration
Jimmie C. Holland, MD, of Memorial Sloan Kettering Cancer Center, and Tammy A. Schuler, PhD, of the Association for Behavioral and Cognitive Therapies, demonstrate a dialogue between a clinician and a recently diagnosed cancer patient whose distress was discovered with the use of the Distress...
Karen Kelly, MD, on PD-1 Axis Inhibition and the Treatment of Advanced Disease
Karen Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse events, and corticosteroid use; and an evaluation of disease-related symptoms in patients treated with nivolumab or...
Philip Bonomi, MD, on SBRT and Surgery for Localized Disease
Philip Bonomi, MD, of Rush Medical College, summarizes a debate on two important issues: choosing between surgery and stereotactic body radiation therapy (SBRT) in operable NSCLC, and whether or not to use SBRT for nonbiopsied lung nodules (Abstract PC 01).
Philip Bonomi, MD, on Results of the Romana 1 and Romana 2 Trials
Philip Bonomi, MD, of Rush Medical College, summarizes the findings on anamorelin and its use in advanced NSCLC for improvement in anorexia/cachexia symptoms (Abstracts ORAL 29.01, ORAL 29.02).
Matteo Lambertini, MD, on Preserving Women’s Fertility Through Hormonal Therapy
Matteo Lambertini, MD, Dana-Farber Cancer Institute, discusses the use of LHRH agonists during chemotherapy to suppress ovarian function as a way to preserve fertility in breast cancer patients (Abstract 1957).
Christopher Brian Allard, MD, on Prostate Cancer Risk and Regular Aspirin Use
Christopher Brian Allard, MD, of Brigham & Women's Hospital, reports on results of the Physicians’ Health Study, which showed that regular aspirin use decreased the risk of lethal prostate cancer in a cohort of American doctors (Abstract 306).
Matthew Smith, MD, PhD, on Bone Metastases: Treatment Update
Matthew Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses the best use of approved therapies for tumors that have spread to the bone.
Erin Elizabeth Hahn, PhD, MPH, on Hodgkin Lymphoma: Post-Treatment Services
Erin Elizabeth Hahn, PhD, MPH, of Kaiser Permanente Southern California, discusses the use of recommended post-treatment services for adolescent and young adult Hodgkin lymphoma survivors (Abstract 107).
Evolution
Ten years ago, ASCO created the Journal of Oncology Practice to address a gap in the literature; there were no peer-reviewed journals dedicated to the practical issues of delivering quality oncology care. The original research and editorials published in JOP focus on care delivery topics such as...
Famed Cancer Biostatistician, Norman Breslow, PhD, Dies
A longitudinal case-controlled analysis of the probability of attaining normality after achieving 60: A perspective from the social sciences based on expert ethnographic insights.” So begins a long and charmingly erudite birthday card to internationally regarded biostatistician Norman Breslow, PhD, ...
Same Study, Different Interpretations
An article in The New York Times1 about an ovarian cancer screening study published in The Lancet2 is headlined, “Early Detection of Ovarian Cancer May Become Possible,” and leads with the promise of reduced mortality with multimodal screening for ovarian cancer. An article in MedPage Today3 about...
Could a Screening Test That Would Reduce Deaths From Ovarian Cancer Be on the Way?
"A solid triple but not a home run” is how Karen H. Lu, MD, characterized a study in The Lancet reporting a reduction in deaths from ovarian cancer with the use of multimodal ovarian cancer screening.1 Dr. Lu’s remark was one of several, mostly but not universally, favorable and optimistic comments ...
Rakesh Jain, PhD, and Mary-Claire King, PhD, Awarded the National Medal of Science
Rakesh Jain, PhD, the A. Werk Cook Professor of Radiation Oncology (Tumor Biology) at Harvard Medical School and Massachusetts General Hospital, and Mary-Claire King, PhD, Professor of Genome Sciences and Medicine (Medical Genetics) at the University of Washington, have been selected as recipients...
Pieces of Grief
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
